Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02074631 · ClinicalTrials.gov registry record · Phase 2
Prevention of Bone Loss After Pediatric Hematopoietic Cell Transplantation
A Phase 2 study, sponsored by Masonic Cancer Center, University of Minnesota.
- Completed
- Registry status
- Phase 2
- Development phase
- 63
- Enrollment target
NCT02074631 is a Phase 2 study that has completed, run by Masonic Cancer Center, University of Minnesota. The registered enrollment target is 63 participants.
The verdict
NCT02074631, a Phase 2 study, has completed, sponsored by Masonic Cancer Center, University of Minnesota.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 63 participants
- Enrollment target
Study Summary
This is a Phase 2, open-label, randomized, controlled clinical study of pediatric subjects treated with pamidronate with calcium and vitamin D versus calcium and vitamin D alone following hematopoietic cell transplantation (HCT). The purpose of this study is to test the hypothesis that subjects receiving pamidronate with calcium and vitamin D will have higher lumbar spine bone mineral content (LBMC) measured by dual-energy X-ray tomography (DXA) at 1 year post-HCT than subjects receiving calcium and vitamin D alone (Control Group).
Interventions
- DRUG Pamidronate
- DRUG Calcium and vitamin D
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 63 participants |
| Start Date | 2015-02 |
| Est. Completion | 2022-10-06 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02074631
The ClinicalTrials.gov registry entry for NCT02074631 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 63 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Masonic Cancer Center, University of Minnesota, which has 249 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Pamidronate is the first listed.
NCT02074631 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02074631 about?
NCT02074631 is a clinical study titled "Prevention of Bone Loss After Pediatric Hematopoietic Cell Transplantation". This is a Phase 2, open-label, randomized, controlled clinical study of pediatric subjects treated with pamidronate with calcium and vitamin D versus calcium and vitamin D alone following hematopoietic cell transplantation (HCT). The purpose of this study is to test the hypothesis that subjects rece...
What is the current status of trial NCT02074631?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 63 participants. The study started on 2015-02. Estimated completion is 2022-10-06.
What interventions are being tested in trial NCT02074631?
The interventions under investigation include: Pamidronate (DRUG), Calcium and vitamin D (DRUG).
Who is sponsoring clinical trial NCT02074631?
This trial is sponsored by Masonic Cancer Center, University of Minnesota, which has 249 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.